Review anchor
Growth hormone-releasing hormone receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Growth hormone-releasing hormone receptor
CHEMBL2032
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Growth hormone-releasing hormone receptor as ChEMBL target CHEMBL2032, mapped to UniProt Q02643. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2032
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q02643
Growth hormone-releasing hormone receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Growth hormone-releasing hormone receptor matters
Growth hormone-releasing hormone receptor is reviewed as Growth hormone-releasing hormone receptor (UniProt Q02643); Growth hormone-releasing hormone receptor shows approved-linked disease relevance led by HIV-Associated Lipodystrophy Syndrome.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 3 compounds, and 3 assays, with lead potency reaching pChEMBL 9.8.
Protein context
Growth hormone-releasing hormone receptor
Growth hormone-releasing hormone receptor Sequence length is 423 aa.
Review this target as Growth hormone-releasing hormone receptor, mapped to UniProt Q02643. Sequence length is 423 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q02643
Protein
Disease context
HIV-Associated Lipodystrophy Syndrome
Growth hormone-releasing hormone receptor shows approved-linked disease relevance led by HIV-Associated Lipodystrophy Syndrome. 1 linked drug keep the rationale reviewable. Linked drugs include TESAMORELIN ACETATE.
Start review with HIV-Associated Lipodystrophy Syndrome because it currently carries approved-linked support. Linked drugs include TESAMORELIN ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 3 compounds, and 3 assays for this target. The dominant activity type is IC50. CHEMBL3545252 is the current potency anchor at pChEMBL 9.8.
Use CHEMBL3545252 as the tractability anchor when discussing potency (pChEMBL 9.8).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 9.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Growth hormone-releasing hormone receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q02643, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why HIV-Associated Lipodystrophy Syndrome is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
3
Total Compounds
3
Total Assays
1
Approved Drugs
IC50: 1.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3545252
|
9.8 | IC50 | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
DOCETAXEL
CHEMBL3545252
|
1995 |
Source Header